Discover
BMS-986165 / BMSBMS-986165 clinical trial estimate: Data from P2 trial (NCT03881059) for PsA in April 2020 (Morgan Stanley) - Dec 12, 2019 - A subscription to Thomson ONE is required to gain full access to report 68264181; Page no: 8; REPORT TITLE: "Novartis AG- Pharmaceuticals: Specialist prescribing dynamics: Focus on immunology”; AUTHOR: Purcell, Mark, et al; DATE: 11/05/2019BMS-986165 / BMSAn Investigational Study to Evaluate Experimental Medication BMS-986165 Compared to Placebo in Participants With Plaque Psoriasis (POETYK-PSO-3) in Mainland China, Taiwan, and South Korea (clinicaltrials.gov) - Dec 11, 2019 - P3; N=180; Recruiting; Sponsor: Bristol-Myers Squibb; Not yet recruiting --> RecruitingIlumya (tildrakizumab-asmn) / Sun Pharma, AlmirallIlumya sales projection: $175M by FY2022 (Nomura) - Dec 16, 2019 - A subscription to Thomson ONE is required to gain full access to report 68399991; Page no: 1; REPORT TITLE: "Sun Pharmaceutical Industries (SUNP IN, Buy) - Retain buy with reduced TP of INR 525"; AUTHOR: Mukherjee, Saion, et al; DATE: 11/25/2019bimekizumab (UCB4940) / UCBBimekizumab sales projection: €1.3B peak by 2027 and €764M in 2024 (Kepler Cheuvreux) - Dec 12, 2019 - A subscription to Thomson ONE is required to gain full access to report 68117973; Page no: 1; REPORT TITLE: "UCB SA- Espresso note | UCB | Buy | First success for key asset bimekizumab”; AUTHOR: Evans, David, et al; DATE: 10/17/2019Otezla (apremilast) / AmgenOtezla sales projection: $3.4B in 2025 (Oppenheimer) - Dec 10, 2019 - A subscription to Thomson ONE is required to gain full access to report 68429540; Page no: 1; REPORT TITLE: "Amgen Inc - Recent events bolster our Outlook”; AUTHOR: Research Department; DATE: 12/01/2019Stelara (ustekinumab) / J&J; Tremfya (guselkumab) / J&JStelara and Tremfya Pregnancy Exposure Registry OTIS Autoimmune Diseases in Pregnancy Project (clinicaltrials.gov) - Dec 13, 2019 - P=N/A; N=200; Recruiting; Sponsor: University of California, San Diego; Active, not recruiting --> Recruiting; N=107 --> 200; Trial completion date: Jul 2022 --> Dec 2025; Trial primary completion date: Nov 2020 --> Dec 2024Otezla (apremilast) / AmgenAPPROPIATE: Study to Evaluate the Benefits for the Patient Associated With the Treatment of Plaque Psoriasis With Apremilast After Other Systemic Treatment in Conditions of Clinical Practice in Spain (clinicaltrials.gov) - Dec 13, 2019 - P=N/A; N=153; Active, not recruiting; Sponsor: Celgene; Recruiting --> Active, not recruiting; Trial primary completion date: Jul 2019 --> Feb 2020Skyrizi (risankizumab) / AbbVie, Boehringer IngelheimIMMpact2: A Study Comparing Risankizumab to Placebo in Subjects With Active Psoriatic Arthritis Including Those Who Have a History of Inadequate Response or Intolerance to Biologic Therapy(Ies) (clinicaltrials.gov) - Dec 11, 2019 - P3; N=420; Recruiting; Sponsor: AbbVie; Trial completion date: Dec 2024 --> May 2024bimekizumab (UCB4940) / UCBBimekizumab share value projection: €17/share to UCB (Kepler Cheuvreux) - Dec 12, 2019 - A subscription to Thomson ONE is required to gain full access to report 68117973; Page no: 1; REPORT TITLE: "UCB SA- Espresso note | UCB | Buy | First success for key asset bimekizumab”; AUTHOR: Evans, David, et al; DATE: 10/17/2019BMS-986165 / BMS; Stelara (ustekinumab) / J&JEfficacy and Safety of BMS-986165 Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) (clinicaltrials.gov) - Dec 11, 2019 - P2; N=180; Active, not recruiting; Sponsor: Bristol-Myers Squibb; Recruiting --> Active, not recruiting
